验证并完善 2022 年欧洲白血病网络(European LeukaemiaNet)对接受异体造血细胞移植的急性髓性白血病患者进行的遗传风险分类

IF 12.8 1区 医学 Q1 HEMATOLOGY Leukemia Pub Date : 2024-10-28 DOI:10.1038/s41375-024-02440-2
Weihao Chen, Lieguang Chen, Yang Cao, Chuanhe Jiang, Yi Luo, Guifang Ouyang, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, Jimin Shi, Xiaoxia Hu, He Huang, Yanmin Zhao
{"title":"验证并完善 2022 年欧洲白血病网络(European LeukaemiaNet)对接受异体造血细胞移植的急性髓性白血病患者进行的遗传风险分类","authors":"Weihao Chen, Lieguang Chen, Yang Cao, Chuanhe Jiang, Yi Luo, Guifang Ouyang, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, Jimin Shi, Xiaoxia Hu, He Huang, Yanmin Zhao","doi":"10.1038/s41375-024-02440-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"38 12","pages":"2712-2716"},"PeriodicalIF":12.8000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation\",\"authors\":\"Weihao Chen, Lieguang Chen, Yang Cao, Chuanhe Jiang, Yi Luo, Guifang Ouyang, Jian Yu, Yamin Tan, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Yishan Ye, Luxin Yang, Congxiao Zhang, Jimin Shi, Xiaoxia Hu, He Huang, Yanmin Zhao\",\"doi\":\"10.1038/s41375-024-02440-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18109,\"journal\":{\"name\":\"Leukemia\",\"volume\":\"38 12\",\"pages\":\"2712-2716\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-10-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41375-024-02440-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41375-024-02440-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

共有757名新生急性髓细胞白血病患者符合培训队列的条件,其中男性401人,女性356人,异体器官移植后的中位随访时间为30个月(1-91个月)。allo-HCT时的中位年龄为40岁(14-69岁)。根据ELN2022分类,34%(n = 257)为良好,42%(n = 316)为中等,24%(n = 180)为不良。与ELN2017的分类相比,ELN2022分类中95%的有利患者、80%的中等患者和84%的不利患者仍处于先前的风险分层中。从ELN2017到ELN2022的患者和主要突变类型的重新分布见图1B和表S1,详细的基线人口统计学数据见表S2。根据ELN2017,有利组、中间组和不利组的3年累积复发率(CIR)分别为13%、18%和40%,相应的无复发生存率(RFS)分别为81%、75%和52%,总生存率(OS)分别为85%、81%和59%,差异均有统计学意义(P <0.001)(图1C、E、G)。在ELN2022中,有利组、中间组和不利组的3年CIR分别为11%、19%和40%(P< 0.001);3年RFS分别为84%、74%和52%(P< 0.001);3年OS分别为88%、79%和59%(P< 0.001)(图1D、F、H)。如果将生存率分析局限于异体肝移植时获得完全缓解(CR)的患者,也能观察到类似的结果(图 S1)。此外,在多变量模型中,诊断时的ELN2022风险分类是CIR、RFS和OS的独立预后因素(表S3)。为了比较ELN2022和ELN2017风险系统在我们的训练队列中的预后预测能力,我们进行了接收者操作特征(ROC)分析。预测复发(AUCELN2017 = 0.660 vs. AUCELN2022 = 0.668,P = 0.530)、RFS(AUCELN2017 = 0.648 vs. AUCELN2022 = 0.658,P = 0.372)和 OS(AUCELN2017 = 0.641 vs. AUCELN2022 = 0.653,P = 0.318)在 ELN2022 和 ELN2017 之间无明显差异(图 1I-K 和表 S4)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Validation and refinement of the 2022 European LeukaemiaNet genetic risk classification of acute myeloid leukaemia patients receiving allogeneic haematopoietic cell transplantation
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia
Leukemia 医学-血液学
CiteScore
18.10
自引率
3.50%
发文量
270
审稿时长
3-6 weeks
期刊介绍: Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues
期刊最新文献
Correspondence to: “Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations”, Curik N et al. Leukemia. 2024; 38: 1415–1418 VDAC2 primes myeloma cells for BAK-dependent apoptosis and represents a novel therapeutic target STAT6 mutations compensate for CREBBP mutations and hyperactivate IL4/STAT6/RRAGD/mTOR signaling in follicular lymphoma Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma Patterns and variations of copy number alterations in acute myeloid leukemia: insights from the LeukAtlas database
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1